Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Multiple myeloma in post nuclear accident crisis.

Wiwanitkit S, Wiwanitkit V.

Indian J Hematol Blood Transfus. 2012 Jun;28(2):65-6. doi: 10.1007/s12288-012-0147-x. Epub 2012 Feb 14.

2.

A framework for estimating radiation-related cancer risks in Japan from the 2011 Fukushima nuclear accident.

Walsh L, Zhang W, Shore RE, Auvinen A, Laurier D, Wakeford R, Jacob P, Gent N, Anspaugh LR, Schüz J, Kesminiene A, van Deventer E, Tritscher A, del Rosarion Pérez M.

Radiat Res. 2014 Nov;182(5):556-72. doi: 10.1667/RR13779.1. Epub 2014 Sep 24.

PMID:
25251702
3.

Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.

Auel B, Goldschmidt H, Geer T, Moehler TM, Platzbecker U, Naumann R, Blau I, Hänel M, Knauf W, Nückel H, Salwender HJ, Scheid C, Weisel K, Gorschlüter M, Glasmacher A, Schmidt-Wolf IG; German Refractory Myeloma Study Group.

Indian J Hematol Blood Transfus. 2012 Jun;28(2):67-76. doi: 10.1007/s12288-011-0103-1. Epub 2011 Aug 18.

4.

Post-crisis efforts towards recovery and resilience after the Fukushima Daiichi Nuclear Power Plant accident.

Yamashita S, Takamura N.

Jpn J Clin Oncol. 2015 Aug;45(8):700-7. doi: 10.1093/jjco/hyv076. Epub 2015 Jun 8. Review.

PMID:
26059007
5.

Radiological protection issues arising during and after the Fukushima nuclear reactor accident.

González AJ, Akashi M, Boice JD Jr, Chino M, Homma T, Ishigure N, Kai M, Kusumi S, Lee JK, Menzel HG, Niwa O, Sakai K, Weiss W, Yamashita S, Yonekura Y.

J Radiol Prot. 2013 Sep;33(3):497-571. doi: 10.1088/0952-4746/33/3/497. Epub 2013 Jun 27.

PMID:
23803462
6.

Nuclear accident crisis and liver disease: a summary on evidences.

Wiwanitkit V.

World J Nucl Med. 2013 May;12(2):52-3. doi: 10.4103/1450-1147.136691. Review.

7.

The Fukushima radiation accident: consequences for radiation accident medical management.

Meineke V, Dörr H.

Health Phys. 2012 Aug;103(2):217-20. doi: 10.1097/HP.0b013e31825b5809.

PMID:
22951483
8.

[Comparative analysis of the radionuclide composition in fallout after the Chernobyl and the Fukushima accidents].

Kotenko KV, Shinkarev SM, Abramov IuV, Granovskaia EO, Iatsenko VN, Gavrilin IuI, Margulis UIa, Garetskaia OS, Imanaka T, Khoshi M.

Med Tr Prom Ekol. 2012;(10):1-5. Russian.

PMID:
23210176
9.

Paediatrics thyroid cancer in post nuclear accident crisis: roles of paediatrics surgery.

Wiwanitkit V.

Afr J Paediatr Surg. 2011 Sep-Dec;8(3):326. doi: 10.4103/0189-6725.91659. No abstract available.

10.

Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.

Raje N, Faiman B, Harvey RD, Kurtin SE, Lonial S, Kumar SK, Cohen AD, Conde MA, Giralt SA, Recine MS, Tombler ER, Stadtmauer E, Jagannath S, Anderson KC; Managing Myeloma Continuing Education Initiative Advisory Group.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):356-69. doi: 10.1016/j.clml.2014.04.011. Epub 2014 Jun 12.

PMID:
25066040
11.

French policy for managing the post-accident phase of a nuclear accident.

Gallay F, Godet JL, Niel JC.

Ann ICRP. 2015 Jun;44(1 Suppl):172-8. doi: 10.1177/0146645314551670. Epub 2014 Nov 3.

PMID:
25915552
12.

Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.

Reece D, Imrie K, Stevens A, Smith CA; Hematology Disease Site Groupof Cancer Care Ontario’s Program in Evidence-based Care.

Curr Oncol. 2006 Oct;13(5):160-72.

13.

Risk of thyroid cancer after the Fukushima nuclear power plant accident.

Yamashita S, Suzuki S.

Respir Investig. 2013 Sep;51(3):128-33. doi: 10.1016/j.resinv.2013.05.007. Epub 2013 Jul 31. Review.

14.
15.

Hematological aftermath of the radiation accident in Istanbul.

Engin VS, Tufan F, Kalayoglu Besisik S, Engin G, Ozturk M, Ersoy S.

Int J Radiat Biol. 2015;91(9):724-31. doi: 10.3109/09553002.2015.1054527. Epub 2015 Jun 18.

PMID:
25994813
16.

Global and local cancer risks after the Fukushima Nuclear Power Plant accident as seen from Chernobyl: a modeling study for radiocaesium ((134)Cs &(137)Cs).

Evangeliou N, Balkanski Y, Cozic A, Møller AP.

Environ Int. 2014 Mar;64:17-27. doi: 10.1016/j.envint.2013.11.020. Epub 2013 Dec 20.

PMID:
24361922
17.
18.

Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.

Chen MH, Qi C, Reece D, Chang H.

Hum Pathol. 2012 Jun;43(6):858-64. doi: 10.1016/j.humpath.2011.07.013. Epub 2011 Nov 1.

PMID:
22047644
19.

A case control study of multiple myeloma at four nuclear facilities.

Wing S, Richardson D, Wolf S, Mihlan G, Crawford-Brown D, Wood J.

Ann Epidemiol. 2000 Apr;10(3):144-53.

PMID:
10813507
20.

[Medical specialties in crisis: causes of the crisis and possible solutions].

Nirel N, Matzliach R, Birkenfeld S, Benbassat J.

Harefuah. 2008 Jun;147(6):482-7, 576. Hebrew.

PMID:
18693621

Supplemental Content

Support Center